Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-07-15 16:01:00

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 36,142,857 shares of its common stock, including 4,714,285 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $17.50 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $632.5 million. All of the shares of common stock sold in the public offering were sold by Erasca.

DEADLINE ALERT for ERAS, NNOX, MSFT, BRCB: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

2026-07-15 13:14:00

BENSALEM, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

ERAS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

2026-07-15 13:04:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Erasca between January 14, 2025 and April 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 15, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

2026-07-15 12:52:00

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

2026-07-15 12:52:00

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline.

ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

2026-07-15 10:07:00

Erasca Allegedly Raised $258.8 Million Through a Shelf Registration Statement While Concealing Patent Infringement Risk and Improper Preclinical Comparisons for Its Lead Drug Candidate NEW YORK, July 15, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Erasca, Inc. (NASDAQ: ERAS). YOU MAY BE AFFECTED IF YOU: Purchased ERAS stock between January 14, 2025 and April 26, 2026 Lost money on your Erasca investment Acquired shares in or traceable to the Company's January 2026 offering conducted pursuant to a Form S-3 shelf registration statement Find out if you qualify for recovery or contact Joseph E.

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

2026-07-14 22:42:00

NEW YORK and NEW ORLEANS, July 14, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc. (“Erasca” or the “Company”) (NasdaqGS: ERAS) of a class action securities lawsuit.

ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS

2026-07-14 21:44:00

SAN FRANCISCO, July 14, 2026 /PRNewswire/ -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca's pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015. The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026.